Baxter International Inc. (BAX) operates within the global medical technology and healthcare equipment industry, a sector characterized by high regulatory barriers, intensive capital requirements for sterile manufacturing, and a concentrated base of hospital and clinical customers. Following a profound strategic reorganization that culminated in the January 2025 divestiture of its Kidney Care business (Vantive) to the Carlyle Group for approximately $3.4 billion in net after-tax proceeds1, Baxter currently operates through three primary reporting segments:

1. Medical Products & Therapies (MPT): The company’s largest segment, providing intravenous (IV) infusion pumps, IV solutions, and advanced surgical products (such as hemostats and sealants)3.
2. Healthcare Systems & Technologies (HST): Cen ...